Shelly Albaum

Apr 14, 2018

CDXC Answers Third Amended Counterclaims

Today ChromaDex filed its answer to Elysium's Third Amended Counterclaims. You can read the answer here:

ChromaDex's Answer to Elysium's TACC

The answer is mostly just a denial of all material allegations, and there is little new or unexpected as compared to ChromaDex's previous answer to Elysium's Second Amended Counterclaims, with the possible exception of this particular denial:

ChromaDex admits that it provided to some customers, not including Elysium, statements signed by the company’s Director of Quality Assurance attesting to the fact that its nicotinamide riboside was tested for chemicals subject to the requirements of California’s voter initiative. (emphasis added)

This new pleading has been added to our Litigation Documents page.

#CDXC #ChromaDex #ElysiumHealth #Litigation

    1070
    0